PharmaCielo Ltd. ( TSXV: PCLO) (OTCQX: PCLOF)’s Colombia-grown dried flower continues to propagate through Europe with a Czech Republic customer now in line to receive its THC-dominant cultivar.
On Thursday, the cannabis firm headquartered in Toronto but with main operations in Rio Negro, Colombia announced that its subsidiary PharmaCielo Colombia Holdings S.A.S. has made its first shipment to a customer who is an established cannabinoid-focused pharmaceutical distributor and clinical research organization in the country. The unnamed company also imports cannabinoids from The Netherlands and Canada.
“PharmaCielo’s global business development team continues to make substantial progress growing the Company’s sales pipeline and setting the stage for accelerated growth beginning in 2023.
The EU is the biggest opportunity for global cannabinoid exporters, and PharmaCielo is positioned to win market share against current suppliers, with a combination of proprietary Colombian strains, high-quality products and low production costs.”
“Our team has made substantial progress in several markets recently, including Germany, Israel, Brazil, Mexico, Poland, and now the Czech Republic. We expect the combination of these recent developments and sustained sales efforts to make the next eighteen months a pivotal period for the company.”
Read more: PharmaCielo receives certification to start exporting pot to Israel
Read more: PharmaCielo ships pre-commercial CBD isolate to Mexican pharmaceutical
